Vulliemoz, Marianne; Brand, Stephan; Juillerat, Pascal; Mottet, Christian; Ben-Horin, Shomron; Michetti, Pierre (2020). TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. Digestion, 101(S1), pp. 16-26. Karger 10.1159/000506898
Text
506898.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (344kB) |
BACKGROUND
Anti-tumour necrosis factor-alpha (anti-TNF) antagonists have been the mainstay in the treatment of inflammatory bowel diseases (IBDs) for over 20 years.
SUMMARY
This review article aimed to provide an update on recent advances in TNF antagonist therapy for IBDs. Key Messages: Their position in the treatment algorithm has evolved to "rapid step-up therapy" or "top-down therapy" according to disease severity and patients' characteristics. Limitations of anti-TNF antagonists include loss of response in up to 30-50% of patients with or without the development of antibodies. Therapeutic drug monitoring should provide a tailored, personalized approach to this scenario. Recently, biosimilar agents have been approved for IBDs and are considered equivalent in efficacy to the originator.
Item Type: |
Journal Article (Review Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology |
UniBE Contributor: |
Juillerat, Pascal |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0012-2823 |
Publisher: |
Karger |
Language: |
English |
Submitter: |
Rahel Fuhrer |
Date Deposited: |
22 Dec 2020 11:31 |
Last Modified: |
05 Dec 2022 15:42 |
Publisher DOI: |
10.1159/000506898 |
PubMed ID: |
32739923 |
Uncontrolled Keywords: |
Biologicals Crohn’s disease Inflammatory bowel diseases Infliximab TNF inhibitors Ulcerative colitis |
BORIS DOI: |
10.7892/boris.149248 |
URI: |
https://boris.unibe.ch/id/eprint/149248 |